Doximity (DOCS) Competitors

Doximity (NASDAQ:DOCS) and Krystal Biotech (NASDAQ:KRYS) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

Which has better earnings and valuation, DOCS or KRYS?

Doximity has higher revenue and earnings than Krystal Biotech. Doximity is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Doximity	$419.05M	10.61	$112.82M	$0.66	36.11
Krystal Biotech	$50.70M	87.82	$10.93M	$0.08	1,952.37

Do analysts prefer DOCS or KRYS?

Doximity currently has a consensus price target of $28.82, suggesting a potential upside of 20.83%. Krystal Biotech has a consensus price target of $171.00, suggesting a potential upside of 10.01%. Given Doximity's higher probable upside, equities analysts plainly believe Doximity is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Doximity	1 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.07
Krystal Biotech	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is DOCS or KRYS more profitable?

Doximity has a net margin of 29.39% compared to Krystal Biotech's net margin of 0.00%. Doximity's return on equity of 16.08% beat Krystal Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Doximity	29.39%	16.08%	13.76%
Krystal Biotech	N/A	-13.31%	-12.61%

Do institutionals & insiders hold more shares of DOCS or KRYS?

87.2% of Doximity shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 39.4% of Doximity shares are owned by insiders. Comparatively, 14.1% of Krystal Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Does the media favor DOCS or KRYS?

In the previous week, Doximity had 16 more articles in the media than Krystal Biotech. MarketBeat recorded 27 mentions for Doximity and 11 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 0.78 beat Doximity's score of 0.50 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Doximity	8 Very Positive mention(s)	3 Positive mention(s)	14 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Krystal Biotech	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community favor DOCS or KRYS?

Krystal Biotech received 228 more outperform votes than Doximity when rated by MarketBeat users. Likewise, 66.75% of users gave Krystal Biotech an outperform vote while only 41.53% of users gave Doximity an outperform vote.

Company	Underperform	Outperform
Doximity	Outperform Votes 49 41.53%	Underperform Votes 69 58.47%
Krystal Biotech	Outperform Votes 277 66.75%	Underperform Votes 138 33.25%

Which has more volatility & risk, DOCS or KRYS?

Doximity has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500.

Summary

Doximity beats Krystal Biotech on 11 of the 18 factors compared between the two stocks.